Kyowa Kirin Co., Ltd. (KYKOF)
OTCMKTS · Delayed Price · Currency is USD
15.71
0.00 (0.00%)
At close: Feb 9, 2026
Kyowa Kirin Revenue
In the year 2025, Kyowa Kirin had annual revenue of 496.83B JPY with 0.26% growth. Kyowa Kirin had revenue of 147.38B in the quarter ending December 31, 2025, with 11.01% growth.
Revenue
496.83B JPY
Revenue Growth
+0.26%
P/S Ratio
2.79
Revenue / Employee
87.64M JPY
Employees
5,669
Market Cap
8.83B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 496.83B | 1.27B | 0.26% |
| Dec 31, 2024 | 495.56B | 53.33B | 12.06% |
| Dec 31, 2023 | 442.23B | 43.86B | 11.01% |
| Dec 31, 2022 | 398.37B | 46.13B | 13.09% |
| Dec 31, 2021 | 352.25B | 33.89B | 10.65% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| Jushi Holdings | 260.43M |
| Glass House Brands | 196.17M |
| MariMed | 157.38M |
| Elite Pharmaceuticals | 122.89M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
Kyowa Kirin News
- 12 days ago - Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Roctinlimab - GuruFocus
- 12 days ago - Amgen ends collaboration agreement with Kyowa Kirin for eczema asset - Seeking Alpha
- 12 days ago - Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends - Benzinga
- 12 days ago - Kyowa Kirin Regains Global Rights To Atopic Dermatitis Drug After Amgen Collaboration Ends - Benzinga
- 12 days ago - Amgen Inc. (AMGN) Announces Termination of License and Collaboration Agreement with Kyowa Kirin - GuruFocus
- 12 days ago - Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab - Nasdaq
- 12 days ago - Amgen (AMGN) Ends Collaboration with Kyowa Kirin on Rocatinlimab - GuruFocus
- 2 months ago - Kyowa Kirin announces management changes - Seeking Alpha